Inhibition of phosphoinositide 3-kinase δ (PI3Kδ) is an appealing target for several
hematological malignancies and inflammatory diseases. Herein, we describe the discovery …

Aberrant signaling of phosphoinositide 3-kinase δ (PI3Kδ) has been implicated in numerous
pathologies including hematological malignancies and rheumatoid arthritis. Described in …

In recent years, pharmaceutical companies have increasingly focused on phosphoinositide
3-kinases delta (PI3Kδ) and gamma (PI3Kγ) as therapeutic targets for the treatment of …

A high-throughput screening (HTS) campaign identified a class of heteroaryl piperazines
with excellent baseline affinity and selectivity for phosphoinositide 3-kinase δ (PI3Kδ) over …

Inhibition of PI3Kδ is considered to be an attractive mechanism for the treatment of
inflammatory diseases and leukocyte malignancies. Using a structure-based design …

Structure-based rational design led to the synthesis of a novel series of potent PI3K
inhibitors. The optimized pyrrolopyridine analogue 63 was a potent and selective PI3Kβ/δ …

Phosphoinositide 3-kinase δ (PI3Kδ) plays a critical role in B lymphocyte (B-cell)
development and activation and has been a validated target for the treatment of B-cell …

Selective inhibitors of phosphoinositide 3-kinase delta are of interest for the treatment of
inflammatory diseases. Initial optimization of a 3-substituted indazole hit compound targeting …

The predominant expression of phosphoinositide 3-kinase δ (PI3Kδ) in leukocytes and its
critical role in B and T cell functions led to the hypothesis that selective inhibitors of this …

PI3Kδ catalytic activity is required for immune cell activation, and has been implicated in
inflammatory diseases as well as hematological malignancies in which the AKT pathway is …